A Randomized, Double-blinded, Placebo-controlled, Multi-center Phase 2 Study to Explore the Efficacy and Safety of Subcutaneous Injection EG-Myocin Immediately Before and After PCI in Patients with Acute ST-Elevation Myocardial Infarction (STEMI)
- Conditions
- Diseases of the circulatory system
- Registration Number
- KCT0004288
- Lead Sponsor
- Eyegene
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 60
Ability to provide informed consent
- Male : 19 ~ 75 years, Female : 50 ~ 75 years
- ST-segment elevation myocardial infarction
- PPCI
- Able to consent for blood draw
- Left main coronary artery
- Cardiac arrest or arrhythmia where CPR or unscheduled circulatory aids have been used during diagnosis
- Cardiac shock
- uncontrolled hypertension
- CABG, coronary artery bypass graft
- An arrhythmia patient who has clinically significant
- Severe renal disorders
- Severe liver disorders
- Medical history of malignant carcinoma within past 3 years
- Subjects who have hypersensitivity reaction anamnesis for components of Investigational Product.
- Treatment with other investigational agents or devices within the previous 30 days, planned use of investigational drugs or devices, or previous enrolment in this trial
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Inhibitory Effect of Investigational Medicinal Product on Myocardial Ischemia / Reperfusion Injury
- Secondary Outcome Measures
Name Time Method Effect of Investigational Medicinal Product on Physiological Status of Myocardial Infarction